GlobeNewswire Inc.··Zenas Biopharma, Inc.Zenas BioPharma Extends Runway to 2029 Amid Expanded Pipeline Push
Zenas BioPharma reported $718.5M cash position and Q2 2029 runway while advancing multiple clinical programs including obexelimab toward FDA/EMA submissions.
WXXWYZBIOEMA approvalclinical trial